Literature DB >> 4987171

The effect of diphenylhydantoin on thyroxine metabolism in man.

P R Larsen, A J Atkinson, H N Wellman, R E Goldsmith.   

Abstract

The effect of 5,5'-diphenylhydantoin on thyroxine metabolism was examined in five normal volunteers. Intravenous injection of radiothyroxine was followed by a 10-12 day control and subsequent 9-14 day treatment periods. During oral administration of diphenylhydantoin, plasma thyroxine concentration decreased to about 80% of its pretreatment level and the plasma radiothyroxine disappearance rate increased a maximum of 20% over control estimates. These changes were a result of increases in both urinary and fecal excretion of radioisotope.A minimum plasma thyroxine was apparent after 10-12 days of diphenylhydantoin administration. In two of the subjects, treatment was sufficiently prolonged to achieve this new steady state. In these subjects, the decrease in total body thyroxine was balanced by the increase in the fractional turnover rate. As a result, absolute thyroxine degradation during diphenylhydantoin administration was unchanged from the pretreatment values. Plasma ultrafiltration was used to estimate the free thyroxine fraction at regular intervals during the control and treatment periods. During diphenylhydantoin treatment, there was little or no change in this fraction and therefore, absolute free thyroxine decreased. Thyroxine-binding globulin and thyroxine-binding prealbumin capacities remained constant. These results indicate that thyroxine degradation can proceed at a normal rate in subjects receiving diphenylhydantoin despite decreases in plasma free thyroxine concentration. If free thyroxine is the only portion of the hormone available for cellular utilization, then free thyroxine clearance must be increased in these subjects. This increase in clearance could represent either a direct stimulation of peripheral thyroxine metabolism by diphenylhydantoin, or it could reflect the response of intrinsic regulatory systems to a diphenylhydantoin-mediated displacement of thyroxine from thyroxine-binding globulin. Whatever the mechanism for this effect, a decreased free thyroxine value in patients receiving diphenylhydantoin may not imply hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4987171      PMCID: PMC322591          DOI: 10.1172/JCI106339

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Regulation of the peripheral metabolism of the thyroid hormones.

Authors:  S H INGBAR; N FREINKEL
Journal:  Recent Prog Horm Res       Date:  1960

2.  Depression of the serum protein-bound iodine level by diphenylhydantion.

Authors:  J H OPPENHEIMER; L V FISHER; K M NELSON; J W JAILER
Journal:  J Clin Endocrinol Metab       Date:  1961-03       Impact factor: 5.958

3.  Estimation of thyroxine distribution in man.

Authors:  J T Nicoloff; J T Dowling
Journal:  J Clin Invest       Date:  1968-01       Impact factor: 14.808

4.  Decreased serum free thyroxine concentration in patients treated with diphenylhydantoin.

Authors:  W Chin; G C Schussler
Journal:  J Clin Endocrinol Metab       Date:  1968-02       Impact factor: 5.958

5.  The kinetics of distribution between plasma and liver of 131-I-labeled L-thyroxine in man: observations of subjects with normal and decreased serum thyroxine-binding globulin.

Authors:  R R Cavalieri; G L Searle
Journal:  J Clin Invest       Date:  1966-06       Impact factor: 14.808

6.  Determination of the maximal binding capacity and protein concentration of thyroxine-binding prealbumin in human serum.

Authors:  J H Oppenheimer; M Martinez; G Bernstein
Journal:  J Lab Clin Med       Date:  1966-03

7.  Effect of preliminary purification of 131-I-thyroxine on the determination of free thyroxine in serum.

Authors:  G C Schussler; J E Plager
Journal:  J Clin Endocrinol Metab       Date:  1967-02       Impact factor: 5.958

8.  Clinical evaluation of the determination of thyroxine iodine.

Authors:  C E Cassidy; J Benotti; S Peno
Journal:  J Clin Endocrinol Metab       Date:  1968-03       Impact factor: 5.958

9.  Free thyroxine in human serum: simplified measurement with the aid of magnesium precipitation.

Authors:  K Sterling; M A Brenner
Journal:  J Clin Invest       Date:  1966-01       Impact factor: 14.808

10.  Increased thyroxine turnover and thyroidal function after stimulation of hepatocellular binding of thyroxine by phenobarbital.

Authors:  J H Oppenheimer; G Bernstein; M I Surks
Journal:  J Clin Invest       Date:  1968-06       Impact factor: 14.808

View more
  22 in total

Review 1.  Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction.

Authors:  M Strolin Benedetti; R Whomsley; E Baltes; F Tonner
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

Review 2.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

3.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

4.  Effect of phenytoin therapy on thyroid function.

Authors:  J F Finucane; R S Griffiths
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

5.  Changes in thyroid function tests induced by 2 month carbamazepine treatment in L-thyroxine-substituted hypothyroid children.

Authors:  F De Luca; T Arrigo; E Pandullo; M F Siracusano; S Benvenga; F Trimarchi
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

Review 6.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

Review 7.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

8.  Anticonvulsants and thyroid function.

Authors:  P P Yeo; D Bates; J G Howe; W A Ratcliffe; C W Schardt; A Heath; D C Evered
Journal:  Br Med J       Date:  1978-06-17

Review 9.  The effects of drugs on tests of thyroid function.

Authors:  P H Davies; J A Franklyn
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Amphotericin B pharmacokinetics in humans.

Authors:  A J Atkinson; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.